Cindy L Schwartz

Summary

Affiliation: Johns Hopkins University
Country: USA

Publications

  1. ncbi request reprint The management of Hodgkin disease in the young child
    Cindy L Schwartz
    Sidney Kimmel Cancer Center at Johns Hopkins, Baltimore, Maryland 21208, USA
    Curr Opin Pediatr 15:10-6. 2003
  2. ncbi request reprint Special issues in pediatric Hodgkin's disease
    Cindy L Schwartz
    Department of Oncology and Pediatrics, Sidney Kimmel Oncology Center at Johns Hopkins University, Baltimore, MD, USA
    Eur J Haematol Suppl . 2005
  3. pmc Dose-finding study of 153Sm-EDTMP in patients with poor-prognosis osteosarcoma
    David M Loeb
    Division of Pediatric Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, Baltimore, Maryland 21231, USA
    Cancer 115:2514-22. 2009
  4. pmc Tandem dosing of samarium-153 ethylenediamine tetramethylene phosphoric acid with stem cell support for patients with high-risk osteosarcoma
    David M Loeb
    Division of Pediatric Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, Baltimore, Maryland 21231, USA
    Cancer 116:5470-8. 2010
  5. ncbi request reprint Prognostic factors in pediatric Hodgkin disease
    Cindy L Schwartz
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, CMSC 800, 600 North Wolfe Street, Baltimore, MD 21287, USA
    Curr Oncol Rep 5:498-504. 2003
  6. ncbi request reprint APE chemotherapy for children with relapsed Hodgkin disease: a Pediatric Oncology Group trial
    Robert S Wimmer
    Childrens Oncology Group, Arcadia, CA, USA
    Pediatr Blood Cancer 46:320-4. 2006
  7. ncbi request reprint POG 8625: a randomized trial comparing chemotherapy with chemoradiotherapy for children and adolescents with Stages I, IIA, IIIA1 Hodgkin Disease: a report from the Children's Oncology Group
    Faith H Kung
    Pediatric Hematology Oncology, University of California, San Diego, CA 92103, USA
    J Pediatr Hematol Oncol 28:362-8. 2006
  8. ncbi request reprint Dexrazoxane-associated risk for acute myeloid leukemia/myelodysplastic syndrome and other secondary malignancies in pediatric Hodgkin's disease
    Cameron K Tebbi
    Children s Oncology Group, Statistics and Data Center, Arcadia, CA, USA
    J Clin Oncol 25:493-500. 2007

Research Grants

  1. PEDIATRIC ONCOLOGY GROUP MEMBERSHIP
    Cindy Schwartz; Fiscal Year: 2002

Collaborators

Detail Information

Publications8

  1. ncbi request reprint The management of Hodgkin disease in the young child
    Cindy L Schwartz
    Sidney Kimmel Cancer Center at Johns Hopkins, Baltimore, Maryland 21208, USA
    Curr Opin Pediatr 15:10-6. 2003
    ..Targeting molecular mechanisms specific for the Reed-Sternberg cell may allow for less toxic and more efficacious treatments in the future...
  2. ncbi request reprint Special issues in pediatric Hodgkin's disease
    Cindy L Schwartz
    Department of Oncology and Pediatrics, Sidney Kimmel Oncology Center at Johns Hopkins University, Baltimore, MD, USA
    Eur J Haematol Suppl . 2005
    ..This review intends to address the special issues of childhood HD, with the intent of further encouraging understanding that will foster convergence of pediatric and adult treatment paradigms...
  3. pmc Dose-finding study of 153Sm-EDTMP in patients with poor-prognosis osteosarcoma
    David M Loeb
    Division of Pediatric Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, Baltimore, Maryland 21231, USA
    Cancer 115:2514-22. 2009
    ..The purpose of the current study was to determine the maximally tolerated dose of (153)Sm-EDTMP that permits hematopoietic recovery within 6 weeks...
  4. pmc Tandem dosing of samarium-153 ethylenediamine tetramethylene phosphoric acid with stem cell support for patients with high-risk osteosarcoma
    David M Loeb
    Division of Pediatric Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, Baltimore, Maryland 21231, USA
    Cancer 116:5470-8. 2010
    ..The authors conducted a phase 2 study to test safety and response of high-risk osteosarcoma to tandem doses of 153Sm-EDTMP and to determine correlation between radiation delivered by low and high administered activities...
  5. ncbi request reprint Prognostic factors in pediatric Hodgkin disease
    Cindy L Schwartz
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, CMSC 800, 600 North Wolfe Street, Baltimore, MD 21287, USA
    Curr Oncol Rep 5:498-504. 2003
    ..New developments should be directed toward identification of factors associated with biologic mechanisms of disease to facilitate the development of biologically targeted therapies that will be more efficacious and less toxic...
  6. ncbi request reprint APE chemotherapy for children with relapsed Hodgkin disease: a Pediatric Oncology Group trial
    Robert S Wimmer
    Childrens Oncology Group, Arcadia, CA, USA
    Pediatr Blood Cancer 46:320-4. 2006
    ..APE (cytosine arabinoside, cisplatin, etoposide) is a non-cross-resistant regimen with limited toxicities. We evaluated this regimen for patients with recurrent or refractory disease...
  7. ncbi request reprint POG 8625: a randomized trial comparing chemotherapy with chemoradiotherapy for children and adolescents with Stages I, IIA, IIIA1 Hodgkin Disease: a report from the Children's Oncology Group
    Faith H Kung
    Pediatric Hematology Oncology, University of California, San Diego, CA 92103, USA
    J Pediatr Hematol Oncol 28:362-8. 2006
    ..Early response to therapy was associated with higher EFS, a concept that has led to the Children's Oncology Group paradigm of response-based risk-adapted therapy for pediatric Hodgkin disease...
  8. ncbi request reprint Dexrazoxane-associated risk for acute myeloid leukemia/myelodysplastic syndrome and other secondary malignancies in pediatric Hodgkin's disease
    Cameron K Tebbi
    Children s Oncology Group, Statistics and Data Center, Arcadia, CA, USA
    J Clin Oncol 25:493-500. 2007
    ..We evaluated incidence and risk factors of acute myeloid leukemia (AML)/myelodysplastic syndrome (MDS) and second malignant neoplasms (SMNs)...

Research Grants1

  1. PEDIATRIC ONCOLOGY GROUP MEMBERSHIP
    Cindy Schwartz; Fiscal Year: 2002
    ..With the limited numbers of children admitted with any single oncologic diagnosis to an individual institution, it is clear that cooperative clinical research is required if significant advances are to be made. ..